"Ondansetron" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Descriptor ID |
D017294
|
| MeSH Number(s) |
D03.383.129.308.690 D03.633.100.473.144.500 D03.633.300.148.500
|
| Concept/Terms |
Ondansetron Hydrochloride- Ondansetron Hydrochloride
- Hydrochloride, Ondansetron
- Ondansetron Monohydrochloride
- Monohydrochloride, Ondansetron
- Ondansetron Monohydrochloride Dihydrate
- Dihydrate, Ondansetron Monohydrochloride
- Monohydrochloride Dihydrate, Ondansetron
|
Below are MeSH descriptors whose meaning is more general than "Ondansetron".
Below are MeSH descriptors whose meaning is more specific than "Ondansetron".
This graph shows the total number of publications written about "Ondansetron" by people in this website by year, and whether "Ondansetron" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2025 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ondansetron" by people in Profiles.
-
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine. Biomed Res Int. 2015; 2015:497597.
-
Deciphering a neuronal circuit that mediates appetite. Nature. 2012 Mar 14; 483(7391):594-7.
-
A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg. 2007 May; 104(5):1082-9, tables of contents.
-
Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant. 1999 Jul; 24(1):1-4.
-
Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol. 1998; 42(6):497-503.
-
Re-examination of clinical aspects of pharmacoeconomic analysis. Am J Hosp Pharm. 1994 Dec 01; 51(23):2970-3.
-
Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. J Clin Oncol. 1991 Jul; 9(7):1268-74.
-
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm. 1991 May; 48(5):988-92.